Hao Zhao

Gerry (Hao) Zhao’s practice focuses on patent prosecution, patent litigation, and intellectual property transactions.

In patent prosecution and litigation, Gerry advises both Chinese and international companies in various matters including patent application drafting and examination, global patent filing strategies, patent invalidation, patent-related administrative lawsuits, freedom-to-operate analysis, patentability analysis, and patent due diligence, among others. Gerry led the intellectual property due diligence for Innogen Pharmaceutical Group and TYK Medicines in their Hong Kong IPO.

In intellectual property transactions, especially in development and commercialization collaborations and technology licensing transactions in the fields of pharmaceuticals, biotechnology, and medical devices, Gerry also has extensive experience. He has led over 200 technology transactions in this sector, including, but not limited to, Antengene and UCB (over $1.1 billion), Simcere Zaiming and Ipsen (over $1 billion), Simcere Zaiming and NextCure (over $700 million), Nona Biosciences and Candid Therapeutics (over $300 million), Genor Biopharma and TRC 2004 (over $400 million, the first NewCo transaction led by a Chinese law firm), ImmuneOnco and Instil Bio (over $2 billion), MediLink and BioNTech (over $1.8 billion), Joyo Pharmatech and Erasca (over $200 million), Jacobio Pharma and Allist, Imunopharm and Huadong Medicine, Biocytogen and IDEAYA Biosciences, and IASO Bio and Innovent.

2010-2013 Hengrui Pharmaceuticals, R&D

2013-Now JunHe LLP, partner

Member of the All China Bar Association

Gerry has provided services to a wide range of clients in the pharmaceutical field, including but not limited to Ionis, Daiichi Sankyo, Antengene, Earendil Labs, Biocytogen, MediLink, IASO Bio, Zaiming, Genor Biopharma, Jacobio Pharma, Imunopharm, Visirna, Joyo Pharmatech, Usynova, Elpiscience, ImmuneOnco, TYK Medicines, etc.

Represented Antengene in TCE out-licensing deals with UCB;

Represented Zaiming in ADC out-licensing deals with Ipsen;

Represented Zaiming in ADC out-licensing deals with NextCure;

Represented Biocytogen in antibody out-licensing deals with Gilead, Merck, Radiance, Pheon, Myricx, Ona, and Neurocrine, etc.;

Represented Genor Biopharma in its out-licensing deal and equity deal regarding rights to a bi-specific antibody outside the Greater China region;

Represented ImmuneOnco in an out-licensing deal with Instil Bio for rights to two products outside the Greater China region;

Represented Joyo in an out-licensing agreement with Erasca for ex-China rights of a preclinical product;

Represented Usynova in an out-licensing agreement with AstraZeneca for global rights of a preclinical product;

Represented MediLink in its collaboration with BioNTech with respect to MediLink’s ADC platform technology.

Shanghai Jiao Tong University

Master

2007 - 2010

Shanghai Jiao Tong University

Bachelor

2003 - 2007

Leading Partners: Life Sciences and Healthcare

The Legal 500 Greater China

2026

Other Key Lawyers: Intellectual Property

The Legal 500 Greater China

2026

A-List Rising Star

asialaw

2025

Top 30 IP Experts

GCP Profiles

2025

45 under 45 (Intellectual Property)

LegalOne

2025

China Top 15 IP Lawyers

ALB

2024

PRC and the U.S.